Clear Guidance From NICE for Treatment of New Group of Advanced Ovarian Cancer Patients.

PR Newswire Europe, May, 2005

WELWYN GARDEN CITY, England, May 25 /PRNewswire/ -- The National Institute for Health and Clinical Excellence (NICE) of England and Wales has today issued its review guidance on the clinical management of patients who require second-line or subsequent treatment of advanced ovarian cancer (i). The guidance states that Caelyx(R) is the only single agent treatment recommended for patients in the newly-recognised category of partially platinum-sensitive ovarian cancer patients - those patients whose tumours relapse between 6 and 12 months after completion of initial platinum-based chemotherapy. The announcement from NICE also acknowledges that Caelyx(R) is both clinically- and cost-effective.

Ovarian cancer is currently diagnosed in 6900 (ii) women in the UK...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement